{"data":{"ticker":"TXG","slug":"10x-genomics","name":"10x Genomics","exchange":"NASDAQ","sector":"Healthcare","headquarters":"Pleasanton, California","ceo":"Serge Saxonov","employees":1178,"website":"https://www.10xgenomics.com","founded":"2012","layers":[{"slug":"ai-healthcare","name":"AI Healthcare"}],"exposure":{"score":12,"tier":"Peripheral","rationale":"10x Genomics sells single cell and spatial biology instruments and consumables to researchers, with AI powering the analysis software. Value tracks life science tools demand and instrument placements, with AI as an enabling feature rather than the driver."},"quote":{"price":59.28,"change24hPct":2.1,"change7dPct":-15.45,"change30dPct":-23.29,"change1yPct":288.72,"high52w":97.74,"low52w":15.25,"marketCap":7723660288,"peRatio":null,"eps":-0.59,"volume24h":268095637},"nextEarningsDate":"2026-11-05","summary":"10x Genomics is a life sciences tools company. It sells instruments and consumables for single-cell and spatial biology, which let researchers study biological systems cell by cell. Revenue comes from instrument placements and the recurring consumables those instruments use.","explainer":["10x Genomics is a life sciences tools company. It sells instruments and consumables for single-cell and spatial biology, which let researchers study biological systems cell by cell. Revenue comes from instrument placements and the recurring consumables those instruments use.","AI powers the analysis side of its platforms. Products include Chromium for single-cell analysis, Visium for spatial biology, Xenium with AI-driven analysis, and the Cell Ranger software pipeline. The AI software turns raw experimental data into biological insight for researchers.","Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics trades on the NASDAQ, employs roughly 1,200 people, and is led by CEO Serge Saxonov."],"buildoutRole":"10x Genomics sits in the AI Healthcare layer as a research tools maker whose software depends on AI. Its instruments generate huge biological datasets, and AI analysis in tools like Xenium and Cell Ranger is what makes those datasets useful. That said, the company's results track life science research budgets and instrument demand, with AI as an enabling feature rather than the driver. Supercycle scores its AI exposure at 12 out of 100.","faq":[{"q":"What does 10x Genomics do?","a":"10x Genomics sells single-cell and spatial biology instruments and consumables to researchers. Its platforms, including Chromium, Visium, and Xenium, help scientists study complex biological systems, with AI powering the analysis software."},{"q":"How is 10x Genomics exposed to AI?","a":"Lightly. Supercycle scores it 12 out of 100. AI is central to its analysis software, but revenue tracks life science tools demand and instrument placements, so AI is an enabling feature rather than the growth driver."},{"q":"What are 10x Genomics' main products?","a":"Chromium for single-cell analysis, Visium for spatial biology, Xenium with AI-driven analysis, and the Cell Ranger software pipeline. Instruments generate the data and the AI software interprets it for researchers."},{"q":"Where is 10x Genomics headquartered and who leads it?","a":"10x Genomics is headquartered in Pleasanton, California, and led by CEO Serge Saxonov. The company was founded in 2012, trades on the NASDAQ, and employs roughly 1,200 people."}],"history1y":[{"date":"2026-09-28","close":88.5},{"date":"2026-09-29","close":90.04},{"date":"2026-09-30","close":90.36},{"date":"2026-10-01","close":88.76},{"date":"2026-10-02","close":93.5},{"date":"2026-10-05","close":97.74},{"date":"2026-10-06","close":80.66},{"date":"2026-10-07","close":76.1},{"date":"2026-10-08","close":77.28},{"date":"2026-10-09","close":80.65},{"date":"2026-10-12","close":75.19},{"date":"2026-10-13","close":71.79},{"date":"2026-10-14","close":73.1},{"date":"2026-10-15","close":72.39},{"date":"2026-10-16","close":69.86},{"date":"2026-10-19","close":69.89},{"date":"2026-10-20","close":71.46},{"date":"2026-10-21","close":75.59},{"date":"2026-10-22","close":69.75},{"date":"2026-10-23","close":71.55},{"date":"2026-10-26","close":72.96},{"date":"2026-10-27","close":78.02},{"date":"2026-10-28","close":83.62},{"date":"2026-10-29","close":81.55},{"date":"2026-10-30","close":70.11},{"date":"2026-11-02","close":61.63},{"date":"2026-11-03","close":65.29},{"date":"2026-11-04","close":67.52},{"date":"2026-11-05","close":58.06},{"date":"2026-11-06","close":59.28}],"incomeStatements":[{"ticker":"TXG","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","revenue":642823000,"cost_of_revenue":198942000,"gross_profit":443881000,"operating_expense":0,"operating_income":-110885000,"net_income":-43544000,"earnings_per_share":-0.35,"earnings_per_share_diluted":-0.35,"research_and_development":238632000,"selling_general_and_administrative_expenses":316134000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"TXG","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","revenue":610785000,"cost_of_revenue":196303000,"gross_profit":414482000,"operating_expense":0,"operating_income":-194559000,"net_income":-182627000,"earnings_per_share":-1.52,"earnings_per_share_diluted":-1.52,"research_and_development":264698000,"selling_general_and_administrative_expenses":344343000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"TXG","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","revenue":618727000,"cost_of_revenue":209414000,"gross_profit":409313000,"operating_expense":0,"operating_income":-204349000,"net_income":-255099000,"earnings_per_share":-2.18,"earnings_per_share_diluted":-2.18,"research_and_development":270332000,"selling_general_and_administrative_expenses":343330000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"TXG","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","revenue":516409000,"cost_of_revenue":120386000,"gross_profit":396023000,"operating_expense":0,"operating_income":-167944000,"net_income":-166000000,"earnings_per_share":-1.46,"earnings_per_share_diluted":-1.46,"research_and_development":265667000,"selling_general_and_administrative_expenses":298300000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0}],"balanceSheets":[{"ticker":"TXG","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","total_assets":1041365000,"current_assets":684451000,"cash_and_equivalents":473966000,"total_liabilities":245039000,"current_liabilities":153454000,"total_debt":84361000,"shareholders_equity":796326000,"retained_earnings":-1510591000},{"ticker":"TXG","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","total_assets":918636000,"current_assets":584387000,"cash_and_equivalents":344067000,"total_liabilities":208502000,"current_liabilities":117633000,"total_debt":82613000,"shareholders_equity":710134000,"retained_earnings":-1467047000},{"ticker":"TXG","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","total_assets":965143000,"current_assets":596022000,"cash_and_equivalents":359284000,"total_liabilities":224100000,"current_liabilities":127162000,"total_debt":95370000,"shareholders_equity":741043000,"retained_earnings":-1284420000},{"ticker":"TXG","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","total_assets":1028980000,"current_assets":635035000,"cash_and_equivalents":219746000,"total_liabilities":223237000,"current_liabilities":130957000,"total_debt":95176000,"shareholders_equity":805743000,"retained_earnings":-1029321000}],"holders13f":[{"slug":"cathie-wood","personName":"Cathie Wood","fundName":"ARK Investment Management","value":383517223,"portfolioPct":0.024900370582591355,"change":"trimmed","period":"2026-06-30"},{"slug":"stanley-druckenmiller","personName":"Stanley Druckenmiller","fundName":"Duquesne Family Office","value":15455000,"portfolioPct":0.003549430207936209,"change":"new","period":"2026-06-30"},{"slug":"ray-dalio","personName":"Ray Dalio","fundName":"Bridgewater Associates","value":512798,"portfolioPct":0.000021036928933153076,"change":"trimmed","period":"2026-06-30"}],"news":[{"title":"10x Genomics Inc (TXG) (Q3 2026) Earnings Call Highlights: Atera Launch Takes Flight as Revenue ...","source":null,"url":"https://finance.yahoo.com/healthcare/articles/10x-genomics-inc-txg-q3-171349479.html?.tsrc=rss","date":"2026-11-06"},{"title":"10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis","source":null,"url":"https://finance.yahoo.com/technology/ai/articles/10x-genomics-launches-sentira-ai-155400677.html?.tsrc=rss","date":"2026-11-06"},{"title":"What 10x Genomics (TXG) Said on Its Q3 Earnings Call","source":null,"url":"https://www.marketbeat.com/instant-alerts/transcript-what-10x-genomics-txg-said-on-its-q3-earnings-call-2026-11-06/?utm_source=yahoofinance&utm_medium=yahoofinance&.tsrc=rss","date":"2026-11-06"},{"title":"10x Genomics (TXG) Q3 2026 Earnings Call Transcript","source":null,"url":"https://www.fool.com/earnings/call-transcripts/2026/11/06/10x-genomics-txg-q3-2026-earnings-call-transcript/?.tsrc=rss","date":"2026-11-06"},{"title":"Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/compared-estimates-10x-genomics-txg-233003630.html?.tsrc=rss","date":"2026-11-05"},{"title":"10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/10x-genomics-txg-reports-q3-214503329.html?.tsrc=rss","date":"2026-11-05"},{"title":"10x Genomics: Q3 Earnings Snapshot","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/10x-genomics-q3-earnings-snapshot-214458563.html?.tsrc=rss","date":"2026-11-05"},{"title":"10x Genomics Reports Third Quarter 2026 Financial Results","source":null,"url":"https://finance.yahoo.com/healthcare/articles/10x-genomics-reports-third-quarter-210500999.html?.tsrc=rss","date":"2026-11-05"}]},"meta":{"version":"v1","asOf":"2026-11-06","builtAt":"2026-11-08T15:24:45.650Z","tier":"free","source":"https://supercyclehq.com/stock/10x-genomics","disclaimer":"Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI.","license":"Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset."},"links":{"self":"https://supercyclehq.com/api/v1/stocks/TXG","html":"https://supercyclehq.com/stock/10x-genomics","md":"https://supercyclehq.com/stock/10x-genomics.md","docs":"https://supercyclehq.com/api/v1/openapi.json"}}